Cargando…

Intravitreal bevacizumab injections versus dexamethasone implant for treatment-naïve retinal vein occlusion related macular edema

PURPOSE: To compare the short-term effects of three monthly intravitreal bevacizumab (IVB) injections to single dexamethasone (DEX) implantation in treatment-naïve patients with cystoid macular edema (CME) secondary to branch (BRVO) and central retinal vein occlusion (CRVO). DESIGN: A retrospective...

Descripción completa

Detalles Bibliográficos
Autores principales: Laine, Ilkka, Lindholm, Juha-Matti, Ylinen, Petteri, Tuuminen, Raimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5708292/
https://www.ncbi.nlm.nih.gov/pubmed/29225460
http://dx.doi.org/10.2147/OPTH.S144688
_version_ 1783282619677409280
author Laine, Ilkka
Lindholm, Juha-Matti
Ylinen, Petteri
Tuuminen, Raimo
author_facet Laine, Ilkka
Lindholm, Juha-Matti
Ylinen, Petteri
Tuuminen, Raimo
author_sort Laine, Ilkka
collection PubMed
description PURPOSE: To compare the short-term effects of three monthly intravitreal bevacizumab (IVB) injections to single dexamethasone (DEX) implantation in treatment-naïve patients with cystoid macular edema (CME) secondary to branch (BRVO) and central retinal vein occlusion (CRVO). DESIGN: A retrospective single-center study. SUBJECTS: A total of 135 eyes of 135 patients with BRVO (n=83) and CRVO (n=52). METHODS: Changes in clinical parameters were recorded before treatment and at the first and third month after commencement of IVB (n=121) and DEX (n=14). MAIN OUTCOME MEASURES: Central retinal thickness (CRT), intraocular pressure (IOP), and best-corrected visual acuity (BCVA). RESULTS: The baseline parameters were comparable between IVB and DEX groups. After the first month, CRT decreased by 131.3±42.9 μm in IVB and by 266.9±48.3 μm in DEX (mean ± SEM; p=0.047). IOP change was –0.29±0.39 mmHg in IVB and +3.70±2.34 mmHg in DEX (p=0.005). IOP elevation to ≥25 mmHg and ≥5 mmHg from the baseline was observed in two of the DEX- and in none of the IVB-treated eyes (p=0.010). After the third month, no differences regarding CRT and IOP were observed between the treatment modalities. Moreover, BCVA gain was comparable between IVB (0.37±0.05 logarithm of minimum angle of resolution [logMAR] units) and DEX (0.33±0.30 logMAR units) groups. CONCLUSION: DEX was associated with faster resolution of CME, but had greater probability for short-term IOP elevation when compared to IVB. After the third month, treatments were comparably effective. Anatomical outcomes and adverse drug reactions of IVB versus DEX should be considered case specifically in patients having CME secondary to BRVO/CRVO.
format Online
Article
Text
id pubmed-5708292
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-57082922017-12-08 Intravitreal bevacizumab injections versus dexamethasone implant for treatment-naïve retinal vein occlusion related macular edema Laine, Ilkka Lindholm, Juha-Matti Ylinen, Petteri Tuuminen, Raimo Clin Ophthalmol Original Research PURPOSE: To compare the short-term effects of three monthly intravitreal bevacizumab (IVB) injections to single dexamethasone (DEX) implantation in treatment-naïve patients with cystoid macular edema (CME) secondary to branch (BRVO) and central retinal vein occlusion (CRVO). DESIGN: A retrospective single-center study. SUBJECTS: A total of 135 eyes of 135 patients with BRVO (n=83) and CRVO (n=52). METHODS: Changes in clinical parameters were recorded before treatment and at the first and third month after commencement of IVB (n=121) and DEX (n=14). MAIN OUTCOME MEASURES: Central retinal thickness (CRT), intraocular pressure (IOP), and best-corrected visual acuity (BCVA). RESULTS: The baseline parameters were comparable between IVB and DEX groups. After the first month, CRT decreased by 131.3±42.9 μm in IVB and by 266.9±48.3 μm in DEX (mean ± SEM; p=0.047). IOP change was –0.29±0.39 mmHg in IVB and +3.70±2.34 mmHg in DEX (p=0.005). IOP elevation to ≥25 mmHg and ≥5 mmHg from the baseline was observed in two of the DEX- and in none of the IVB-treated eyes (p=0.010). After the third month, no differences regarding CRT and IOP were observed between the treatment modalities. Moreover, BCVA gain was comparable between IVB (0.37±0.05 logarithm of minimum angle of resolution [logMAR] units) and DEX (0.33±0.30 logMAR units) groups. CONCLUSION: DEX was associated with faster resolution of CME, but had greater probability for short-term IOP elevation when compared to IVB. After the third month, treatments were comparably effective. Anatomical outcomes and adverse drug reactions of IVB versus DEX should be considered case specifically in patients having CME secondary to BRVO/CRVO. Dove Medical Press 2017-11-27 /pmc/articles/PMC5708292/ /pubmed/29225460 http://dx.doi.org/10.2147/OPTH.S144688 Text en © 2017 Laine et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Laine, Ilkka
Lindholm, Juha-Matti
Ylinen, Petteri
Tuuminen, Raimo
Intravitreal bevacizumab injections versus dexamethasone implant for treatment-naïve retinal vein occlusion related macular edema
title Intravitreal bevacizumab injections versus dexamethasone implant for treatment-naïve retinal vein occlusion related macular edema
title_full Intravitreal bevacizumab injections versus dexamethasone implant for treatment-naïve retinal vein occlusion related macular edema
title_fullStr Intravitreal bevacizumab injections versus dexamethasone implant for treatment-naïve retinal vein occlusion related macular edema
title_full_unstemmed Intravitreal bevacizumab injections versus dexamethasone implant for treatment-naïve retinal vein occlusion related macular edema
title_short Intravitreal bevacizumab injections versus dexamethasone implant for treatment-naïve retinal vein occlusion related macular edema
title_sort intravitreal bevacizumab injections versus dexamethasone implant for treatment-naïve retinal vein occlusion related macular edema
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5708292/
https://www.ncbi.nlm.nih.gov/pubmed/29225460
http://dx.doi.org/10.2147/OPTH.S144688
work_keys_str_mv AT laineilkka intravitrealbevacizumabinjectionsversusdexamethasoneimplantfortreatmentnaiveretinalveinocclusionrelatedmacularedema
AT lindholmjuhamatti intravitrealbevacizumabinjectionsversusdexamethasoneimplantfortreatmentnaiveretinalveinocclusionrelatedmacularedema
AT ylinenpetteri intravitrealbevacizumabinjectionsversusdexamethasoneimplantfortreatmentnaiveretinalveinocclusionrelatedmacularedema
AT tuuminenraimo intravitrealbevacizumabinjectionsversusdexamethasoneimplantfortreatmentnaiveretinalveinocclusionrelatedmacularedema